Reginster J Y, Jeugmans-Huynen A M, Wouters M, Sarlet N, McIntyre H D, Franchimont P
Department of Rheumatology and Endocrinology, University of Liège, Belgium.
Br J Rheumatol. 1992 Jan;31(1):35-9. doi: 10.1093/rheumatology/31.1.35.
Thirty pagetic patients were treated for 6 months with a daily nasal application of 2 mg of synthetic human calcitonin (hCT). Serum alkaline phosphatases (SAP) and urinary hydroxyproline/creatinine ratio (OH/Cr), reflecting bone turnover, were significantly reduced from the first month of treatment (mean +/- SEM: SAP, -13.9 +/- 2.2%; OH/Cr, -22.2 +/- 5.8%; both P less than 0.01) and until the end of the 6-month course (mean +/- SEM: SAP, -29.7 +/- 4.6%; OH/Cr, -22.5 +/- 5.9%; both P less than 0.01). Nasal hCT was perfectly tolerated both locally and systemically. These results allow us to consider nasal hCT for long-term trials in metabolic bone diseases characterized by a relative increase of bone resorption.
30名变形性骨炎患者每日经鼻应用2毫克合成人降钙素（hCT）进行为期6个月的治疗。反映骨转换的血清碱性磷酸酶（SAP）和尿羟脯氨酸/肌酐比值（OH/Cr）从治疗的第一个月起就显著降低（平均值±标准误：SAP，-13.9±2.2%；OH/Cr，-22.2±5.8%；两者P均小于0.01），并且一直持续到6个月疗程结束（平均值±标准误：SAP，-29.7±4.6%；OH/Cr，-22.5±5.9%；两者P均小于0.01）。经鼻hCT在局部和全身都具有良好的耐受性。这些结果使我们能够考虑将经鼻hCT用于以骨吸收相对增加为特征的代谢性骨病的长期试验。
